Macquarie sees limited commission-rule risk as PB Fintech gains insurance share
Macquarie retained Outperform and a ₹1,950 target for Policybazaar parent PB Fintech, citing FY26 insurance-linked revenue of ₹5,811 crore, up 41% year on year. It expects new products and operating leverage to lift EBITDA margin toward 16% by FY28; Bernstein also sees regulatory relief.
What happened
PB Fintech (Policybazaar) · Brokerages expect proposed Indian insurance commission rules to have limited impact on PB Fintech. Macquarie highlighted FY26
Key facts
- PB Fintech insurance commission-pool share: 6% in FY26 vs 4% in FY25
- FY26 insurance-linked revenue: Rs 5,811 crore, up 41% YoY from Rs 4,129 crore
- General insurance revenue: Rs 2,786 crore, up 50% YoY
- Life insurance revenue: Rs 1,726 crore, up 24% YoY
- Standalone health revenue: Rs 1,245 crore, up 43% YoY
- Standalone health commission-pool share: 20% in FY26 vs 16% in FY25
- Macquarie target price: Rs 1,950
- Expected EPS CAGR: about 58% from FY26-FY28
- Expected EBITDA margin: about 16% by FY28
Why this matters
PB Fintech’s growing insurance share and regulatory resilience strengthen its strategic value as a distribution partner, though commission-rule implementation remains a key diligence item.
What to watch
- Final IRDAI commission and expense-management rules, including implementation timing and product-level exemptions.
- Quarterly insurance premium growth, insurance revenue growth and disclosed take-rate trends.
- Renewal revenue mix, health and protection-product mix, and cross-sell penetration.
- Customer-acquisition cost, conversion rates and marketing spend as a percentage of revenue.
- EBITDA margin progression versus the path toward approximately 16% by FY28.
- Insurer partner additions, changes in carrier commission structures and any reduction in product availability.
- Competitive pricing and marketing activity from bank-led, insurer-owned and digital insurance distributors.
- Increase focus on renewal-led revenue, health insurance and protection products, which can reduce reliance on upfront commissions.
- Use new insurer and product launches to raise conversion, cross-sell and customer lifetime value rather than pursue growth solely through paid acquisition.
- Negotiate revised commercial structures with insurers, including service fees, performance-linked payouts and retention incentives.
- Continue operating-cost discipline so incremental revenue converts into EBITDA even if take rates face modest pressure.
- Use regulatory clarity to reinforce investor messaging around normalized unit economics and FY28 margin trajectory.